SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending amidst widespread user frustration over persistent platform outages and trading restrictions on its ThinkorSwim and mobile apps, leading many to consider alternative brokers, even as the company reports strong financial performance, including a substantial share buyback and strategic acquisitions into private markets.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending sharply higher following a strong earnings report that highlighted record user growth, expanding margins, and the success of its Wrapped campaign, sparking community debate over its transition from a pure growth story to a high-margin cash generator. Many users are pointing to impressive premium subscriber increases and improved profitability as reasons for the stock's significant bounce from its recent lows, viewing it as a major turning point.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

The imminent merger vote for Churchill Capital Corp X with Infleqtion, solidified by SEC approval and a clear timeline to trade as INFQ, is fueling significant investor interest. The community widely views Infleqtion as an undervalued leader in quantum technology, citing its robust government and industry partnerships, including with NASA and NVIDIA, and its superior neutral-atom computing, setting the stage for a potential re-rating against its peers.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after Morgan Stanley initiated coverage with an "Overweight" rating and a $37 price target, fueling optimism for its strategic pivot to high-performance computing and data center infrastructure. The community is actively discussing the company's strong power assets and expansion plans, with many anticipating a significant short squeeze.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to a significant stock drop after a key potential tenant terminated a $150 million funding agreement for its Project Matador data center, despite management indicating ongoing negotiations and plans to accelerate other client deals. The community is actively debating whether this presents a 

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is surging after releasing robust 52-week maintenance data for its atopic dermatitis drug, Rezpeg, showcasing durable efficacy and a clean safety profile. The community is actively discussing the drug's strong competitive positioning, which is further bolstered by recent Nobel Prize recognition validating Treg-based therapies, fueling significant upside potential and buyout speculation.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing significant upward momentum after announcing positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, which met its primary efficacy and safety endpoints. The community is actively discussing strong price targets and potential for a short squeeze, though some caution about the company's valuation and debt for a biotech at this clinical stage.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending after its Q4 earnings report, which, despite an initial sell-off, highlighted strong revenue and GMV growth along with a substantial reduction in cash burn. The community is actively discussing this progress towards profitability by late 2026, viewing the dip as a buying opportunity in the promising African e-commerce market.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as its recent robust earnings beat and impressive high-value client additions are sparking optimism that this could signal a broader recovery for the beleaguered software sector, with many highlighting DDOG's critical role in AI infrastructure.

SSgA Active Trust - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund (XLF) is trending as investors weigh rising consumer loan delinquencies and potential political intervention like a proposed credit card interest rate cap against upcoming bank earnings and hopes for increased share buybacks. The community is split, with some anticipating strong results and others fearing broader credit issues and a looming banking crisis for the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings)

Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 25.4% during the third quarter, according to its most recent disclosure with...

Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year High - Still a Buy?

Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High - What's Next...

Roivant Sciences Q3 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along with a set of broader clinical and corporate milestones, during the...

Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in...

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity.</li><li>The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo.</li><li>Following discussions with the U.S. Food and Drug Administration, Roivant’s subsidiary,&nbsp;Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026.</li></ul>Roivant Sciences (ROIV) on Friday reported encouraging Phase 2 clinical results for its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis, while also releasing its fiscal third quarter (Q3) earnings.&nbsp;The company reported a Q3 revenue of $1.9 million and a loss per share (EPS) of $0.38. Revenue came in below the analysts’ consensus estimate of $6.14 million, while EPS surpassed the consensus, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Positive BEACON Trial Outcomes&nbsp;</h2>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity compared with placebo, demonstrating statistically meaningful benefits as early as four weeks and maintained through week 16.The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo. Despite including the most treatment-resistant patients, the highest-dose group achieved rapid and sustained improvement.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ROIV">Roivant stock</a> traded over 9% higher in Friday’s pre-market.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Updates On Subsidiaries’ Therapy Programs</h2>Following discussions with the U.S. Food and Drug Administration (FDA), Riovant’s subsidiary, Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026. The company has already submitted a New Drug Application for brepocitinib in dermatomyositis and expects additional Phase 3 data in non-infectious uveitis during the second half of 2026.Additionally, the company said Immunovant’s IMVT-1402 program is fully enrolled in a late-stage rheumatoid arthritis study, with results anticipated in 2026.&nbsp;Meanwhile, the firm’s subsidiary Pulmovant’s&nbsp;mosliciguat trial in pulmonary hypertension linked to interstitial lung disease is also fully enrolled.As of Dec. 31, 2025, Roivant reported approximately $4.5 billion in cash andequivalents.ROIV stock has gained over 94% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-looks-to-end-a-five-day-losing-streak-retail-believes-the-next-growth-wave-is-unfolding-now/cZbFfdXR4nD">Nvidia Looks To End A Five-Day Losing Streak – Retail Believes ‘The Next Growth Wave Is Unfolding Now’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen.

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 

Equity

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 


Insights into Roivant Sciences Q3 Earnings

Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) will be releasing its Q3 2026 earnings before the market opens on Friday, February 6. (View Earnings Report at...

Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV

Parkside Financial Bank & Trust trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 46.7% in the third quarter, according to its most recent Form 13F filing with the Securities...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ROIV News

ROIVRoivant Sciences Ltd